



KemPharm Demonstrates its Continuing Commitment to the Niemann-Pick Community with Recent Leadership Changes

As part of executing on our long-term strategy of transforming into a leading rare disease company, KemPharm has recently announced changes to our executive leadership team in support of that mission. We currently have multiple treatments at various stages of development which are intended to address life-altering conditions, and we will continue to seek additional opportunities to expand our pipeline. These changes build upon the strengths of the senior leadership team and have the potential to further enable the team to achieve the Company's key objectives, which include securing regulatory approval for its product candidates and building top-tier commercial capabilities.

Richard W. Pascoe, who has been a member of KemPharm's Board of Directors since 2014, and most recently serving as Executive Chairman, recently stepped into the role of Chief Executive Officer. Travis C. Mickle, Ph.D., remains in the role of President and will continue to support the Company's pipeline build and the planned resubmission of the arimoclomol New Drug Application (NDA) as a scientific advisor. KemPharm also recently announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Among the recent changes, Joshua Schafer has been appointed to the newly created role of Chief Commercial Officer and Executive Vice President of Business Development. In this role, Josh will oversee all activities needed to ensure patient access to arimoclomol upon approval by regulatory authorities.

Josh brings to KemPharm over 25 years of pharmaceutical commercial, new product development and merger and acquisition (M&A) experience. Joshua previously served as General Manager of the Autoimmune and Rare Disease business at Mallinckrodt Pharmaceuticals, and prior to that, he served as Chief Strategy and Business Officer. Prior to Mallinckrodt, Josh served as Vice President and Oncology Therapeutic Area Head, Global Marketing and Strategy at Astellas Pharmaceuticals, where he was responsible for building the company's global oncology franchise. Joshua currently serves as a Board member of Pharnext SA



and Shuttle Pharmaceuticals. He received his B.A. in Biology and German at the University of Notre Dame, and both an M.S. in Biotechnology and an M.B.A. from Northwestern University.

“I am excited to join KemPharm at this critical point in its evolution and I look forward to working closely with the NPC community to address the urgent unmet need for a treatment option. Having worked with NPC advocates, families, researchers and physicians in the past I am acutely aware of the challenges faced by the community, and I am deeply committed to making treatment options available. I look forward to leading the launch of arimoclomol, subject to regulatory approval, as well as leading the effort to expand our rare disease pipeline,” said Josh.

Our key priorities for the NPC community are simple: (i) continuing and full support of the compassionate use of arimoclomol for the treatment of NPC via our Early Access Programs in the US and several EU countries, (ii) resubmission of the arimoclomol NDA to the FDA, and (iii) evaluation and identification of a regulatory pathway to approval for arimoclomol with the European Medicines Agency (“EMA”).

“KemPharm understands the importance of continuing to provide access to arimoclomol through our Expanded Access Programs in the U.S. and Europe, given the continuing unmet need in the treatment of NPC, and supporting these programs remains a top priority. In addition, I am excited to welcome leaders like Josh to the team who have vast experience and success in the rare disease space. Building upon the strength of our team with leaders like Josh, who bring vast experience in the rare disease space, further demonstrates our dedication to the NPC community,” said Tara Greene, Sr. Director of Medical Operations and US Patient Advocacy. “We are pleased to continue support the work of the NNPDF and other organizations focused on patient advocacy.”

Members of the KemPharm leadership team look forward to attending the 19th Annual WORLD Symposium in February 2023 in Orlando, FL. KemPharm plans to participate in several scientific sessions, including data presentations on NPC and arimoclomol, and learn from Lysosomal Storage Disorders researchers and thought leaders from around the world. Our team looks forward to opportunities to engage with NNPDF and INPDA leadership along with other NPC and rare disease advocacy organizations. We are excited to continue our collaboration going forward and remain committed to bringing much needed solutions to those living with NPC.

Full Press Releases: [KemPharm Organizational Changes](#) and [KemPharm Executive Promotions](#).